POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.12.2021, 3:33pm CEST, WHO):   U.S. 13,304    India 84,332    Brazil 88,092    France 3,639    Turkey 6,261    Russia 13,510    The United Kingdom 7,958    Italy 1,892    Argentina 27,628    Germany 1,911    Columbia 29,302    Iran 9,966    Mexico 3,672    Ukraine 1,274    Peru 4,054    Indonesia 8,083    South Africa 8,020    The Netherlands 1,417    Chile 7,941    Canada 1,476    Philippines 6,686    Iraq 4,320    Pakistan 1,303    Bangladesh 2,454    Japan 1,920    Malaysia 6,849    Nepal 2,709    United Arab Emirates 2,281    Saudi Arabia 1,175    Ecuador 1,098    Belarus 1,026    Bolivia 3,233    Paraguay 2,758    Tunisia 2,161    Costa Rica 2,041    Uruguay 3,622    Kuwait 1,657    Dominican Republic 1,129    Guatemala 1,861    Venezuela 1,083    Sri Lanka 2,789    Thailand 3,277    Cuba 1,288    Zambia 2,065    Afghanistan 1,024    Mongolia 1,622    Namibia 1,432    Botswana 1,392    Uganda 1,566    China 322    Singapore 9    New Zealand 0    Australia 3    South Korea 565   

U.S. begins final tests of coronavirus vaccine candidate

Christian Fernsby |
Phase three trials began on Monday of a candidate vaccine against the novel coronavirus in the U.S., with an expected enrollment of 30,000 volunteers, the National Institutes of Health announced.

Article continues below



Topics: U.S.   

The vaccine was codeveloped by biotechnology company Moderna, Inc., based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID).

The trial will be conducted at 89 U.S. clinical research sites with adult volunteers who do not have coronavirus, according to the statement.

NIAID Director Anthony Fauci said results from earlier clinical testing indicated that the vaccine was "safe and immunogenic, supporting the initiation of a Phase 3 clinical trial."

"This scientifically rigorous, randomized, placebocontrolled trial is designed to determine if the vaccine can prevent COVID-19 and for how long such protection may last."

The vaccine efficacy trial is the first to be implemented under Operation Warp Speed, a governmental program that aims to begin delivering millions of doses of an effective virus vaccine by the end of 2020.

The trial is designed to determine if the vaccine can prevent symptomatic COVID-19 after two doses and it aims to study whether the vaccine can prevent severe infection with or without disease symptoms, the NIH said.

It also seeks to answer whether the vaccine can prevent death caused by the virus and if just one dose can prevent symptomatic COVID-19, among other objectives.

Trial volunteers will receive two injections approximately 28 days apart and some participants will be assigned at random to a control group that will be administered placebo doses.


What to read next

3-in-1 vaccine against traveler's diarrhea
Candidate Ebola vaccine still effective when highly diluted
Zika vaccine works in early human trial